skip to main content

S. 2866: TREAT Act


The text of the bill below is as of Sep 28, 2021 (Introduced).


II

117th CONGRESS

1st Session

S. 2866

IN THE SENATE OF THE UNITED STATES

September 28, 2021

(for himself, Mr. Scott of Florida, Mr. Marshall, Mr. Cramer, Mrs. Blackburn, Mr. Braun, and Mr. Tuberville) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To prohibit the Secretary of Health and Human Services from restricting direct access by health care facilities to COVID–19 monoclonal antibody therapies.

1.

Short title

This Act may be cited as the Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act.

2.

Prohibition on restrictions on direct access to COVID–19 monoclonal antibody therapies

(a)

In general

Notwithstanding any other provision of law, the Secretary of Health and Human Services (referred to in this section as the Secretary) may not implement or continue in effect any policy that would restrict hospitals or other appropriate health care facilities from ordering and receiving COVID–19 monoclonal antibody therapies directly from manufacturers and distributors of such therapies.

(b)

Nullification of certain policy

Pursuant to subsection (a), effective on the date of enactment of this Act, the policy under which the Secretary required hospitals and other facilities to work through State or territorial governments to receive supplies of COVID–19 monoclonal antibody therapies allocated by the Secretary to such States or territories, announced by such Secretary on September 13, 2021, shall have no force or effect.